Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms
Authors:Patrick Van Dijck1,2,‡, Jelmer Sjollema3,‡, Bruno P.A. Cammue4,5, Katrien Lagrou6,7, Judith Berman8, Christophe d’Enfert9, David R. Andes10,11, Maiken C. Arendrup12-14, Axel A. Brakhage15, Richard Calderone16, Emilia Cantón17, Tom Coenye18,19, Paul Cos20, Leah E. Cowen21, Mira Edgerton22, Ana Espinel-Ingroff23, Scott G. Filler24, Mahmoud Ghannoum25, Neil A.R. Gow26, Hubertus Haas27, Mary Ann Jabra-Rizk28, Elizabeth M. Johnson29, Shawn R. Lockhart30, Jose L. Lopez-Ribot31, Johan Maertens32, Carol A. Munro26, Jeniel E. Nett33, Clarissa J. Nobile34, Michael A. Pfaller35,36, Gordon Ramage19,37, Dominique Sanglard38, Maurizio Sanguinetti39, Isabel Spriet40, Paul E. Verweij41, Adilia Warris42, Joost Wauters43, Michael R. Yeaman44, Sebastian A.J. Zaat45, Karin Thevissen4,*
1 VIB-KU Leuven Center for Microbiology, Leuven, Belgium.
2 KU Leuven Laboratory of Molecular Cell Biology, Leuven, Belgium.
3 University of Groningen, University Medical Center Groningen, Department of BioMedical Engineering, Groningen, The Netherlands.
4 Centre for Microbial and Plant Genetics, KU Leuven, Leuven, Belgium.
5 Department of Plant Systems Biology, VIB, Ghent, Belgium.
6 Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
7 Clinical Department of Laboratory Medicine and National Reference Center for Mycosis, UZ Leuven, Belgium.
8 School of Molecular Cell Biology and Biotechnology, Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Israel.
9 Institut Pasteur, INRA, Unité Biologie et Pathogénicité Fongiques, Paris, France.
10 Department of Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
11 Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
12 Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark.
13 Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
14 Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
15 Leibniz Institute for Natural Product Research and Infection Biology – Hans Knoell Institute (HKI), Dept. Microbiology and Molecular Biology, Friedrich Schiller University Jena, Institute of Microbiology, Jena, Germany.
16 Department of Microbiology & Immunology, Georgetown University Medical Center, Washington DC, USA.
17 Severe Infection Research Group: Medical Research Institute La Fe (IISLaFe), Valencia, Spain.
18 Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.
19 ESCMID Study Group for Biofilms, Switzerland.
20 Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Belgium.
21 Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
22 Department of Oral Biology, School of Dental Medicine, University at Buffalo, Buffalo, NY USA.
23 VCU Medical Center, Richmond, VA, USA.
24 Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
25 Center for Medical Mycology, Department of Dermatology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, USA.
26 MRC Centre for Medical Mycology, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
27 Biocenter – Division of Molecular Biology, Medical University Innsbruck, Innsbruck, Austria.
28 Department of Oncology and Diagnostic Sciences, School of Dentistry; Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, USA.
29 National Infection Service, Public Health England, Mycology Reference Laboratory, Bristol, UK.
30 Centers for Disease Control and Prevention, Atlanta, GA, USA.
31 Department of Biology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, USA.
32 Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium and Clinical Department of Haematology, UZ Leuven, Leuven, Belgium.
33 University of Wisconsin-Madison, Departments of Medicine and Medical Microbiology & Immunology, Madison, WI, USA.
34 Department of Molecular and Cell Biology, School of Natural Sciences, University of California, Merced, Merced, USA.
35 Departments of Pathology and Epidemiology, University of Iowa, Iowa, USA.
36 JMI Laboratories, North Liberty, Iowa, USA.
37 College of Medical, Veterinary and Life Sciences, University of Glasgow, UK.
38 Institute of Microbiology, University of Lausanne and University Hospital, CH-1011 Lausanne
39 Institute of Microbiology, Università Cattolica del Sacro Cuore, IRCCS-Fondazione Policlinico “Agostino Gemelli”, Rome, Italy.
40 Pharmacy Dpt, University Hospitals Leuven and Clinical Pharmacology and Pharmacotherapy, Dpt. of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium.
41 Center of Expertise in Mycology Radboudumc/CWZ, Radboud University Medical Center, Nijmegen, the Netherlands (omit “Nijmegen” in Radboud University Medical Center).
42 MRC Centre for Medical Mycology, Aberdeen Fungal Group, University of Aberdeen, Foresterhill, Aberdeen, UK.
43 KU Leuven-University of Leuven, University Hospitals Leuven, Department of General Internal Medicine, Herestraat 49, B-3000 Leuven, Belgium.
44 Geffen School of Medicine at the University of California, Los Angeles, Divisions of Molecular Medicine & Infectious Diseases, Harbor-UCLA Medical Center, LABioMed at Harbor-UCLA Medical Center.
45 Department of Medical Microbiology, Amsterdam Infection and Immunity Institute, Academic Medical Center, University of Amsterdam, Netherlands.
‡ Equally contributing
Keywords:
antifungal susceptibility testing, biofilm inhibition, biofilm eradication, antibiofilm material coating, in vivo models
Related Article(s)?
Corresponding Author(s):
Conflict of interest statement:
The authors declare no conflict of interest.
Please cite this article as:
Patrick Van Dijck, Jelmer Sjollema, Bruno P.A. Cammue, Katrien Lagrou, Judith Berman, Christophe d’Enfert, David R. Andes, Maiken C. Arendrup, Axel A. Brakhage, Richard Calderone, Emilia Cantón, Tom Coenye, Paul Cos, Leah E. Cowen, Mira Edgerton, Ana Espinel-Ingroff, Scott G. Filler, Mahmoud Ghannoum, Neil A.R. Gow, Hubertus Haas, Mary-Ann Jabra-Rizk, Elizabeth M. Johnson, Shawn R. Lockhart, Jose L. Lopez-Ribot, Johan Maertens, Carol A. Munro, Jeniel E. Nett, Clarissa J. Nobile, Michael A. Pfaller, Gordon Ramage, Dominique Sanglard, Maurizio Sanguinetti, Isabel Spriet, Paul Verweij, Adilia Warris, Joost Wauters, Michael R. Yeaman, Sebastiaan A.J. Zaat, Karin Thevissen (2018). Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell X(Y): in press.
© 2018 Van Dijck et al. This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the original author and source are acknowledged.
Abstract:
Unlike superficial fungal infections of the skin and nails, which are the most common fungal diseases in humans, invasive fungal infections carry high morbidity and mortality, particularly those associated with biofilm formation on indwelling medical devices. Therapeutic management of these complex diseases is often complicated by the rise in resistance to the commonly used antifungal agents. Therefore, the availability of accurate susceptibility testing methods for determining antifungal resistance, as well as discovery of novel antifungal and antibiofilm agents, are key priorities in medical mycology research. To direct advancements in this field, here we present an overview of the methods currently available for determining (i) the susceptibility or resistance of fungal isolates or biofilms to antifungal or antibiofilm compounds and compound combinations; (ii) the in vivo efficacy of antifungal and antibiofilm compounds and compound combinations; and (iii) the in vitro and in vivo performance of anti-infective coatings and materials to prevent fungal biofilm-based infections.
doi: 10.15698/mic2018.07.638
Volume 5, pp. 300 to 326, published 14/06/2018.